PLYMOUTH (WWJ) — Esperion Therapeutics Inc. (Nasdaq: ESPR) says its shares have been added to the Nasdaq Biotechnology Index effetive Dec. 23.
Esperion is working on new drugs that can be taken in pill form to reduce low-density lipoprotein, the so-called bad cholesterol, in the blood.
Esperion’s stock is also part of the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Esperion’s lead product candidate, ETC 1002, is currently in clinical trials. It is intended to reduce cholesterol levels for people who cannot tolerate the side effects of today’s statin drugs.
More at http://www.esperion.com.